Background: The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non–small-cell lung-cancer (NSCLC) with a programmed death-ligand 1 (PD-L1) expression of ≥ 50%. Patients and Methods: We previously conducted a multicenter retrospective analysis in patients with treatment-naive metastatic NSCLC and a PD-L1 expression of ≥ 50% receiving first-line pembrolizumab. Here, we report the results of the irAE analysis and the potential correlation between irAEs and clinical outcomes. Results: A total of 1010 patients were included in this analysis; after a 6-week landmark selection, 877 (86.8%) patients were included in the efficacy analysis. Any grade irAEs (P <.0001), grade 3/4 irAEs (P =.0025), leading to discontinuation irAEs (P =.0144), multiple-site and single-site irAEs (P <.0001), cutaneous irAEs (P =.0001), endocrine irAEs (P =.0227), pulmonary irAEs (P =.0479), and rheumatologic irAEs (P =.0018) were significantly related to a higher objective response rate. Any grade irAEs (P <.0001), single-site irAEs (P <.0001), multiple-site irAEs (P =.0005), cutaneous irAEs (P =.0042), endocrine irAEs (P <.0001), gastrointestinal irAEs (P =.0391), and rheumatologic irAEs (P =.0086) were significantly related to progression-free survival. Any grade irAEs (P <.0001), single-site irAEs (P <.0001), multiple-site irAEs (P =.0003), cutaneous irAEs (P =.0002), endocrine irAEs (P =.0001), and rheumatologic irAEs (P =.0214) were significantly related to overall survival. Conclusions: This study confirms the feasibility and the safety of first-line, single-agent pembrolizumab, in a large, real-world cohort of patients with NSCLC with PD-L1 expression ≥ 50%. The occurrence of irAEs may be a surrogate of clinical activity and improved outcomes in this setting.

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Bria E.;Galetta D.;Passiglia F.;Marchetti P.;Santoni M.;Catino A.;Cantini L.;De Filippis M.;Cecchi C.;Ricciardi S.;Addeo A.;Morabito A.;Santini D.;
2020-01-01

Abstract

Background: The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non–small-cell lung-cancer (NSCLC) with a programmed death-ligand 1 (PD-L1) expression of ≥ 50%. Patients and Methods: We previously conducted a multicenter retrospective analysis in patients with treatment-naive metastatic NSCLC and a PD-L1 expression of ≥ 50% receiving first-line pembrolizumab. Here, we report the results of the irAE analysis and the potential correlation between irAEs and clinical outcomes. Results: A total of 1010 patients were included in this analysis; after a 6-week landmark selection, 877 (86.8%) patients were included in the efficacy analysis. Any grade irAEs (P <.0001), grade 3/4 irAEs (P =.0025), leading to discontinuation irAEs (P =.0144), multiple-site and single-site irAEs (P <.0001), cutaneous irAEs (P =.0001), endocrine irAEs (P =.0227), pulmonary irAEs (P =.0479), and rheumatologic irAEs (P =.0018) were significantly related to a higher objective response rate. Any grade irAEs (P <.0001), single-site irAEs (P <.0001), multiple-site irAEs (P =.0005), cutaneous irAEs (P =.0042), endocrine irAEs (P <.0001), gastrointestinal irAEs (P =.0391), and rheumatologic irAEs (P =.0086) were significantly related to progression-free survival. Any grade irAEs (P <.0001), single-site irAEs (P <.0001), multiple-site irAEs (P =.0003), cutaneous irAEs (P =.0002), endocrine irAEs (P =.0001), and rheumatologic irAEs (P =.0214) were significantly related to overall survival. Conclusions: This study confirms the feasibility and the safety of first-line, single-agent pembrolizumab, in a large, real-world cohort of patients with NSCLC with PD-L1 expression ≥ 50%. The occurrence of irAEs may be a surrogate of clinical activity and improved outcomes in this setting.
2020
21
6
498
508.e2
First line; irAEs; NSCLC; PD-L1; Pembrolizumab
Cortellini A.; Friedlaender A.; Banna G.L.; Porzio G.; Bersanelli M.; Cappuzzo F.; Aerts J.G.J.V.; Giusti R.; Bria E.; Cortinovis D.; Grossi F.; Migliorino M.R.; Galetta D.; Passiglia F.; Berardi R.; Mazzoni F.; Di Noia V.; Signorelli D.; Tuzi A.; Gelibter A.; Marchetti P.; Macerelli M.; Rastelli F.; Chiari R.; Rocco D.; Inno A.; Di Marino P.; Mansueto G.; Zoratto F.; Santoni M.; Tudini M.; Ghidini M.; Filetti M.; Catino A.; Pizzutilo P.; Sala L.; Occhipinti M.A.; Citarella F.; Marco R.; Torniai M.; Cantini L.; Follador A.; Sforza V.; Nigro O.; Ferrara M.G.; D'Argento E.; Leonetti A.; Pettoruti L.; Antonuzzo L.; Scodes S.; Landi L.; Guaitoli G.; Baldessari C.; Bertolini F.; Della Gravara L.; Dal Bello M.G.; Belderbos R.A.; De Filippis M.; Cecchi C.; Ricciardi S.; Donisi C.; De Toma A.; Proto C.; Addeo A.; Cantale O.; Ricciuti B.; Genova C.; Morabito A.; Santini D.; Ficorella C.; Cannita K.
File in questo prodotto:
File Dimensione Formato  
Clin Lung Cancer.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 628.79 kB
Formato Adobe PDF
628.79 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1770082
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 50
  • ???jsp.display-item.citation.isi??? 44
social impact